Plain-English translation of NCT06556693 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a new implanted device called the remedē® Dual Channel System, which is designed to help people with severe sleep apnea breathe better during sleep. The device works by stimulating nerves that control breathing. Researchers want to see if this treatment is safe and whether it works well for patients with severe sleep apnea.
Sleep apnea is a serious condition where breathing repeatedly stops during sleep, and current treatment options don't work for everyone. This trial exists to find out if this new implanted device can offer patients a safe and effective alternative way to manage their condition.
You likely qualify if…
You likely don't qualify if…
You would undergo surgery to have the remedē® Dual Channel System implanted. Before and after implant, you would complete overnight sleep studies to measure how well the device works and track any side effects. The study will monitor your safety over time to ensure the treatment is well-tolerated and effective for managing your sleep apnea.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States
Sponsor
Zoll Medical Corporation
Enrollment target
~40 participants
Started
August 2025
Primary completion
April 2028
Age range
22 Years and older
Last updated on clinicaltrials.gov in October 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Samuel Kolapo
ZOLL Respicardia
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.